Citations

Showing 10 of 108162 citations.

Autologous Adipose Tissue–Derived Mesenchymal Stem Cells Introduced by Biliary Stents or Local Immersion in Porcine Bile Duct Anastomoses
Zhang, Yi , Sharma, Ayushman , Joo, Dong Jin , Nelson, Erek , AbuRmilah, Anan , Amiot, Bruce , Boyer, Christen J., Jalan‐Sakrikar, Nidhi , Martin, John A. , Moreira, Roger K. , Chowdhury, Shiraj A. , Smart, Michele, Dietz, Allan B. , Nyberg, Scott L. , Amiot, Bruce P, Jalan-Sakrikar, Nidhi, Martin, John, Moreira, Roger, Huebert, Robert , Dietz, Allan B , Abu Rmilah, Anan A , Sakrikar, Nidhi Jalan , Zhang, Yi, Alexander, J. Steven , Heimbach, Julie K. , Huebert, Robert C.

Mayo Clinic

Liver Transplantation | November 19, 2019 | Volume: 26 | Issue: 1 | Pages: 100-112

10.1002/lt.25682 | PMID 31742878 Get It

Biliary complications (strictures and leaks) represent major limitations in living donor liver transplantation. Mesenchymal stem cells (MSCs) are a promising modality to prevent biliary complications because of immunosuppressive and angiogenic properties. Our goal was to evaluate the safety of adipose‐derived MSC delivery to biliary anastomoses in a porcine model. Secondary objectives were defining the optimal method of delivery (intraluminal versus extraluminal) and to investigate MSC engraftment, angiogenesis, and fibrosis. Pigs were divided into 3 groups. Animals underwent adipose collection, MSC isolation, and expansion. Two weeks later, animals underwent bile duct transection, reanastomosis, and stent insertion. Group 1 received plastic stents wrapped in unseeded Vicryl mesh. Group 2 received stents wrapped in MSC‐seeded mesh. Group 3 received unwrapped stents with the anastomosis immersed in an MSC suspension. Animals were killed 1 month after stent insertion when cholangiograms and biliary tissue were obtained. Serum was collected for liver biochemistries. Tissue was used for hematoxylin‐eosin and trichrome staining and immunohistochemistry for MSC markers (CD44 and CD34) and for a marker of neoangiogenesis (CD31). There were no intraoperative complications. One pig died on postoperative day 3 due to acute cholangitis. All others recovered without complications. Cholangiography demonstrated no biliary leaks and minimal luminal narrowing. Surviving animals exhibited no symptoms, abnormal liver biochemistries, or clinically significant biliary stricturing. Group 3 showed significantly greater CD44 and CD34 staining, indicating MSC engraftment. Fibrosis was reduced at the anastomotic site in group 3 based on trichrome stain. CD31 staining of group 3 was more pronounced, supporting enhanced neoangiogenesis. In conclusion, adipose‐derived MSCs were safely applied to biliary anastomoses. MSCs were locally engrafted within the bile duct and may have beneficial effects in terms of fibrosis and angiogenesis.
Physician practices in Accountable Care Organizations are more likely to collect and use physician performance information, yet base only a small proportion of compensation on performance data
Rosenthal, Meredith B. , Shah, Nilay D. , Peiris, David , Lewis, Valerie A. , Barrera, Jacob A., Usadi, Benjamin , Colla, Carrie H. , Rosenthal, Meredith , Lewis, Valerie A , Usadi, Benjamin , Colla, Carrie H , Shortell, Stephen M.

Mayo Clinic

Health Services Research | November 19, 2019 | Volume: 54 | Issue: 6 | Pages: 1214-1222

10.1111/1475-6773.13238 | PMID 31742688 Get It

AbstractImportanceIt is critical to develop a better understanding of the strategies provider organizations use to improve the performance of frontline clinicians and whether ACO participation is associated with differential adoption of these tools.ObjectivesCharacterize the strategies that physician practices use to improve clinician performance and determine their association with ACOs and other payment reforms.Data SourcesThe National Survey of Healthcare Organizations and the National Survey of ACOs fielded 2017‐2018 (response rates = 47 percent and 48 percent).Study DesignDescriptive analysis for practices participating and not participating in ACOs among 2190 physician practice respondents. Linear regressions to examine characteristics associated with counts of performance domains for which a practice used data for feedback, quality improvement, or physician compensation as dependent variables. Logistic and fractional regression to examine characteristics associated with use of peer comparison and shares of primary care and specialist compensation accounted for by performance bonuses, respectively.Principal FindingsACO‐affiliated practices feed back clinician‐level information and use it for quality improvement and compensation on more performance domains than non‐ACO‐affiliated practices. Performance measures contribute little to physician compensation irrespective of ACO participation.ConclusionACO‐affiliated practices are using more performance improvement strategies than other practices, but base only a small fraction of compensation on quality or cost.
PSMA ADC monotherapy in patients with progressive metastatic castration‐resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in open‐label single‐arm phase 2 study
Petrylak, Daniel P. , Chatta, Kamal, Fleming, Mark T. , Smith, David C. , Hussain, Arif , Modiano, Manuel, Tagawa, Scott T. , Gore, Ira , McClay, Edward F., Mega, Anthony , Somer, Bradley G. , Olson, William C. , Stambler, Nancy , Israel, Robert J. , Singh, Parminder , Sartor, A Oliver , DiPippo, Vincent A , Tagawa, Scott T , Singh, Parminder , Vogelzang, Nicholas J. , Appleman, Leonard J. , Singh, Parminder Pal , Sartor, Oliver , Wadlow, Raymond Couric , Shore, Neal D.

Mayo Clinic

The Prostate | November 19, 2019 | Volume: 80 | Issue: 1 | Pages: 99-108

10.1002/pros.23922 | PMID 31742767 Get It

AbstractBackgroundProstate‐specific membrane antigen (PSMA) is a well‐established therapeutic and diagnostic target overexpressed in both primary and metastatic prostate cancers. PSMA antibody‐drug conjugate (PSMA ADC) is a fully human immunoglobulin G1 anti‐PSMA monoclonal antibody conjugated to monomethylauristatin E, which binds to PSMA‐positive cells and induces cytotoxicity. In a phase 1 study, PSMA ADC was well tolerated and demonstrated activity as measured by reductions in serum prostate‐specific antigen (PSA) and circulating tumor cells (CTCs). To further assess PSMA ADC, we conducted a phase 2 trial in metastatic castration‐resistant prostate cancer (mCRPC) subjects who progressed following abiraterone/enzalutamide (abi/enz) therapy.MethodsA total of 119 (84 chemotherapy‐experienced and 35 chemotherapy‐naïve) subjects were administered PSMA ADC 2.5 or 2.3 mg/kg IV q3w for up to eight cycles. Antitumor activity (best percentage declines in PSA and CTCs from baseline and tumor responses through radiological imaging), exploratory biomarkers, and safety (monitoring of adverse events [AEs], clinical laboratory tests, and Eastern Cooperative Oncology Group performance status) were assessed.ResultsPSA declines ≥50% occurred in 14% of all treated (n = 113) and 21% of chemotherapy‐naïve subjects (n = 34). CTC declines ≥50% were seen in 78% of all treated (n = 77; number of subjects with ≥5 CTCs at baseline and a posttreatment result) and 89% of chemotherapy‐naïve subjects (n = 19); 47% of all treated and 53% of chemotherapy‐naïve subjects had a transition from ≥5 to less than 5 CTCs/7.5 mL blood at some point during the study. PSA and CTC reductions were associated with high PSMA expression (CTCs or tumor tissue) and low neuroendocrine serum markers. In the chemotherapy‐experienced group, the best overall radiologic response to PSMA ADC treatment was stable disease in 51 (60.7%) subjects; 5.7% of subjects in the chemotherapy‐naïve group had partial responses. The most common treatment‐related AEs ≥Common Terminology Criteria for AE (CTCAE) grade 3 were neutropenia, fatigue, electrolyte imbalance, anemia, and neuropathy. The most common serious AEs were dehydration, hyponatremia, febrile neutropenia, and constipation. Two subjects who received 2.5 mg/kg died of sepsis.ConclusionsPSMA ADC demonstrated some activity with respect to PSA declines, CTC conversions/reductions, and radiologic assessments in abi/enz treated mCRPC subjects. Clinically significant treatment‐related AEs included neutropenia and neuropathy.
Faculty Opinions recommendation of Modelling human hepato-biliary-pancreatic organogenesis from the foregut-midgut boundary.
Huebert, Robert C.

Mayo Clinic

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature | November 19, 2019 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3410/f.736664442.793567289 Get It

Impacts of admission serum albumin levels on short-term and long-term mortality in hospitalized patients
Thongprayoon, Charat , Cheungpasitporn, Wisit , Chewcharat, Api , Thirunavukkarasu, Sorkko , Cheungpasitporn, Wisit , Chewcharat, Api , Thongprayoon, Charat , Mao, Michael A. , Kashani, Kianoush

Mayo Clinic

QJM: An International Journal of Medicine | November 19, 2019 | Volume: 113 | Issue: 6 | Pages: 393-398

10.1093/qjmed/hcz305 | PMID 31747010 Get It

Abstract Aim The aim of this study is to assess the association between admission serum albumin and short- and long-term mortality in all hospitalized patients. Design A single-center cohort study. Methods A retrospective cohort of all adult hospitalized patients at a tertiary referral hospital between January 2009 and December 2013 were analysed. Admission serum albumin was stratified into six groups: ≤2.4, 2.5–2.9, 3.0–3.4, 3.5–3.9, 4.0–4.4 and ≥4.5 g/dl. The outcomes of interest were in-hospital mortality, length of hospital stay and 1-year mortality. Serum albumin of 4–4.4 g/dl was selected as a reference group for outcome comparison. Results A total of 14 075 patients were studied. Admission serum albumin of ≥4.5 g/dl had the lowest in-hospital and 1-year mortality with progressively increased in-hospital mortality observed with decreased admission serum albumin. In adjusted analysis, compared with serum albumin of 4.0–4.4 g/dl, serum albumin of ≤2.4, 2.5–2.9, 3.0–3.4 and 3.5–3.9 were significantly associated with increased in-hospital and 1-year mortality. In contrast, serum albumin of ≥4.5 g/dl was significantly associated with lower 1-year mortality but not in-hospital mortality. Admission serum albumin <4.0 g/dl was significantly associated with a prolonged hospital stay, while admission serum albumin of ≥4.5 g/dl was significantly associated with shorter hospital stay, compared with serum albumin of 4.0–4.4 g/dl. Conclusion Low albumin level at admission was progressively associated with increased short- and long-term mortality in all hospitalized patients even when albumin level was considered in normal range.
Parents know best: Caregiver perspectives on eating disorder recovery
Accurso, Erin C. , Sim, Leslie , Muhlheim, Lauren, Lebow, Jocelyn , Accurso, Erin C , Lebow, Jocelyn

Mayo Clinic

International Journal of Eating Disorders | November 19, 2019 | Volume: 53 | Issue: 8 | Pages: 1252-1260

10.1002/eat.23200 | PMID 31743480 Get It

Abstract Objective This study used mixed methods to evaluate caregiver perspectives on recovery from an eating disorder. Method Caregivers ( N = 387) completed an online survey about their child's weight history, treatment history, illness trajectory, and recovery. Results Children were predominantly females with adolescent onset anorexia nervosa and currently 18.4 years old on average. Qualitative analysis of caregivers' open‐ended definitions of recovery revealed seven distinct recovery domains, including (a) weight (45%); (b) body image, eating disorder cognitions, and related emotions (54%); (c) eating behavior (71%); (d) independence and responsibility in eating disorder management (28%); (e) physical health (21%); (f) psychological well‐being (31%); and (g) life worth living (27%). Most (72%) reported that their child had achieved partial or full recovery at some point in their lifetime. Only 20% reported that their child had ever achieved full recovery, but 93% of those had sustained recovery over time (i.e., no relapses since achieving recovery). Physical recovery occurred on average 2.7 years after eating disorder onset, followed shortly by social and emotional recovery (2.9 years), and finally behavioral (3.4 years) and cognitive (3.9 years) recovery, which occurred at weights 6–7 pounds higher than those at which physical recovery was achieved. Discussion Findings suggest that caregivers hold a multifaceted view of recovery that includes not only weight restoration and symptom reduction, but also full engagement in social and occupational activities, establishment of a meaningful life, cognitive flexibility, and emotional well‐being. These data support clinical observations that physical and behavioral recovery precede cognitive recovery.
Patient‐reported outcomes in the Translational Breast Cancer Research Consortium
Bowen, Deborah J. , Shinn, Eileen H. , Gregrowski, Sophie, Kimmick, Gretchen , Dominici, Laura S. , Smith, Karen L. , Rocque, Gabrielle B. , Ruddy, Kathryn J. , Pollastro, Teri, Melisko, Michelle , Ballinger, Tarah J. , Fayanju, Oluwadamilola M. , Smith, Karen Lisa , Rocque, Gabrielle , Fayanju, Oluwadamilola M , Wolff, Antonio C , Frank, Elizabeth S. , Ballinger, Tarah Jean , Wolff, Antonio C.

Mayo Clinic

Cancer | November 19, 2019 | Volume: 126 | Issue: 5 | Pages: 922-930

10.1002/cncr.32615 | PMID 31743427 Get It

Members of the Translational Breast Cancer Research Consortium conducted an expert‐driven literature review to identify a list of domains and to evaluate potential measures of these domains for inclusion in a list of preferred measures. Measures were included if they were easily available, free of charge, and had acceptable psychometrics based on published peer‐reviewed analyses. A total of 22 domains and 52 measures were identified during the selection process. Taken together, these measures form a reliable and validated list of measurement tools that are easily available and used in multiple cancer trials to assess patient‐reported outcomes in relevant patients.
Meeting Report: The Dallas Consensus Conference on Liver Transplantation for Alcohol Associated Hepatitis
Asrani, Sumeet K. , Trotter, James F. , Lake, Jack, Bonagura, Anthony, Cameron, Andrew M. , DiMartini, Andrea F. , Martin, Paul , Mathurin, Philippe , Mellinger, Jessica L. , Rice, John P. , Shah, Vijay H. , Winder, Scott, Klintmalm, Göran B. , DiMartini, Andrea , Im, Gene , Shah, Vijay H , Terrault, Norah , Winder, Scott , Asrani, Sumeet K , Lake, Jack, Ahmed, Aijaz , Gonzalez, Stevan A , Martin, Paul, Terrault, Norah A. , Wall, Anji

Mayo Clinic

Liver Transplantation | November 19, 2019 | Volume: 26 | Issue: 1 | Pages: 127-140

10.1002/lt.25681 | PMID 31743578 Get It

Liver transplantation (LT) for alcohol associated hepatitis (AH) remains controversial. We convened a consensus conference to examine various aspects of LT for AH. The goal was not to unequivocally endorse LT for AH; instead, it was to propose recommendations for programs that perform or plan to perform LT for AH. Criteria were established to determine candidacy for LT in the setting of AH and included the following: (1) AH patients presenting for the first time with decompensated liver disease that are nonresponders to medical therapy without severe medical or psychiatric comorbidities; (2) a fixed period of abstinence prior to transplantation is not required; and (3) assessment with a multidisciplinary psychosocial team, including a social worker and an addiction specialist/mental health professional with addiction and transplantation expertise. Supporting factors included lack of repeated unsuccessful attempts at addiction rehabilitation, lack of other substance use/dependency, acceptance of diagnosis/insight with a commitment of the patient/family to sobriety, and formalized agreement to adhere to total alcohol abstinence and counseling. LT should be avoided in AH patients who are likely to spontaneously recover. Short‐term and longterm survival comparable to other indications for LT must be achieved. There should not be further disparity in LT either by indication, geography, or other sociodemographic factors. Treatment of alcohol‐use disorders should be incorporated into pre‐ and post‐LT care. The restrictive and focused evaluation process described in the initial LT experience for AH worldwide may not endure as this indication gains wider acceptance at more LT programs. Transparency in the selection process is crucial and requires the collection of objective data to assess outcomes and minimize center variation in listing. Oversight of program adherence is important to harmonize listing practices and outcomes.
New Case Detection by Cascade Testing in Familial Hypercholesterolemia
Lee, Christopher , Rivera-Valerio, Miriannie, Bangash, Hana , Prokop, Larry, Rivera-Valerio, Miriannie , Kullo, Iftikhar J.

Mayo Clinic

Circulation: Genomic and Precision Medicine | November 19, 2019 | Volume: 12 | Issue: 11 | Pages: No page available

10.1161/circgen.119.002723 | PMID 31638829 Get It

Background: The prevalence of familial hypercholesterolemia is 1 in 250, but <10% of patients are diagnosed. Cascade testing enables early detection of cases through systematic family tracing. Establishment of familial hypercholesterolemia cascade testing programs in the US could be informed by approaches used elsewhere. Methods: We conducted a systematic review of published studies in the English language of cascade testing for familial hypercholesterolemia, which reported the number of index cases and number of relatives tested and specified methods of contacting relatives and testing modalities methods utilized. For each study, we calculated yield (proportion of relatives who test positive) and new cases per index case, to facilitate comparison. Results: We identified 10 studies from the literature that met inclusion criteria; the mean number of probands and relatives per study was 242 and 826, respectively. The average yield was 44.76% with a range of 30% to 60.5%, and the mean new cases per index case was 1.65 with a range of 0.22 to 8.0. New cases per index case tended to be greater in studies that used direct contact versus indirect contact (2.06 versus 0.86), tested beyond first-degree relatives versus only first-degree relatives (3.65 versus 0.80), used active sample collection versus collection at clinic (4.11 versus 1.06), and utilized genetic testing versus biochemical testing (2.47 versus 0.42). Conclusions: New case detection in familial hypercholesterolemia cascade testing programs tended to be higher with direct contact of relatives, testing beyond first-degree relatives, in-home–based sample collection, and genetic testing. These findings should be helpful for establishing cascade testing programs in the United States.
Molecular Profiles of Matched Primary and Metastatic Tumor Samples Support a Linear Evolutionary Model of Breast Cancer
Chen, Runpu , Goodison, Steve , Sun, Yijun

Mayo Clinic

Cancer Research | November 19, 2019 | Volume: 80 | Issue: 2 | Pages: 170-174

10.1158/0008-5472.can-19-2296 | PMID 31744819 Get It

Abstract The interpretation of accumulating genomic data with respect to tumor evolution and cancer progression requires integrated models. We developed a computational approach that enables the construction of disease progression models using static sample data. Application to breast cancer data revealed a linear, branching evolutionary model with two distinct trajectories for malignant progression. Here, we used the progression model as a foundation to investigate the relationships between matched primary and metastasis breast tumor samples. Mapping paired data onto the model confirmed that molecular breast cancer subtypes can shift during progression and supported directional tumor evolution through luminal subtypes to increasingly malignant states. Cancer progression modeling through the analysis of available static samples represents a promising breakthrough. Further refinement of a roadmap of breast cancer progression will facilitate the development of improved cancer diagnostics, prognostics, and targeted therapeutics. Significance: Analysis of matched primary and metastatic tumor samples supports a unidirectional, linear cancer evolution process and sheds light on longstanding issues regarding the origins of molecular subtypes and their progression relationships.